Correlation Between Mereo BioPharma and Inozyme Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mereo BioPharma and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mereo BioPharma and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mereo BioPharma Group and Inozyme Pharma, you can compare the effects of market volatilities on Mereo BioPharma and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mereo BioPharma with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mereo BioPharma and Inozyme Pharma.

Diversification Opportunities for Mereo BioPharma and Inozyme Pharma

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Mereo and Inozyme is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Mereo BioPharma Group and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Mereo BioPharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mereo BioPharma Group are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Mereo BioPharma i.e., Mereo BioPharma and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Mereo BioPharma and Inozyme Pharma

Given the investment horizon of 90 days Mereo BioPharma Group is expected to generate 0.98 times more return on investment than Inozyme Pharma. However, Mereo BioPharma Group is 1.02 times less risky than Inozyme Pharma. It trades about 0.04 of its potential returns per unit of risk. Inozyme Pharma is currently generating about -0.09 per unit of risk. If you would invest  335.00  in Mereo BioPharma Group on August 24, 2024 and sell it today you would earn a total of  33.00  from holding Mereo BioPharma Group or generate 9.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Mereo BioPharma Group  vs.  Inozyme Pharma

 Performance 
       Timeline  
Mereo BioPharma Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Mereo BioPharma and Inozyme Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mereo BioPharma and Inozyme Pharma

The main advantage of trading using opposite Mereo BioPharma and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mereo BioPharma position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.
The idea behind Mereo BioPharma Group and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities